ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > Coagulation Factor III

Coagulation Factor III

概要

Name:Tissue factor
Target Synonym:Coagulation Factor III (Thromboplastin, Tissue Factor),Thromboplastin,Coagulation Factor III, Tissue Factor,TFA,F3,TF,CD142 Antigen,CD142,Coagulation Factor III,Tissue Factor
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

ACRO Quality

生物活性データの一部

TF3-H5253-SPR
 Coagulation Factor III SPR

Anti-TF mAb immobilized on CM5 Chip can bind Human Tissue Factor, Fc Tag (Cat. No. TF3-H5253) with an affinity constant of 2.38 nM as determined in SPR assay (Biacore T200) (Routinely tested).

TF3-H52H5-SPR
 Coagulation Factor III SPR

Anti-TF mAb immobilized on CM5 Chip via anti-human IgG Fc antibody can bind Human Tissue Factor, His Tag (Cat. No. TF3-H52H5) with an affinity constant of 1.52 nM as determined in SPR assay (Biacore T200) (Routinely tested).

Synonym Name

Coagulation Factor III,Tissue Factor,TF,F3,CD142

Background

Full-length tissue factor (TF) is a transmembrane receptor and cofactor for factor (F)VII/FVIIa. In addition to full-length TF, an alternative spliced (as) form of TF can be generated that lacks the transmembrane domain and is released fromcells. In contrast to TF, asTF has low procoagulant activity because it lacks the transmembrane domain. Tissue factor is expressed by cells around blood vessels, such as adventitial fibroblasts, and body surfaces, such as epithelial cells, and plays a critical role in hemostasis. TF also contributes to various forms of thrombosis. Many cancers, particularly adenocarcinomas, express high levels of TF. A high level of tumor TF expression is associated with poor prognosis in many types of cancers, including breast, prostate, colorectal, and pancreatic cancer.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Tisotumab vedotin TF-011-MMAE Approved Genmab A/S HuMax-TF, TIVDAK United States Uterine Cervical Neoplasms Seagen Inc 2021-09-20 Ovarian Neoplasms; Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
hI-con1 ICON-1; hI-con1 Yale University Details
Recombinant NAPc2 AB-201 Phase 3 Clinical Dendreon Uk Ltd Coronavirus Disease 2019 (COVID-19) Details
MRG004A MRG004A Phase 2 Clinical Shanghai Miracogen Inc Solid tumours Details
XB-002 ICON-2; XB-002 Phase 1 Clinical Iconic Therapeutics Inc Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Urogenital Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details

This web search service is supported by Google Inc.

totopphone